Related Experiment Video

Updated: May 23, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

MicroRNA as a novel drug target for cancer therapy

Xiaoxia Liu1, Li Liu, Qian Xu

  • 1Department of Pharmacy, Southern Medical University, Zhujiang Hospital, 253 Industry Avenue, Guangzhou 510282, PR China.

Expert Opinion on Biological Therapy
|March 21, 2012
PubMed
Abstract

Insights

MicroRNAs (miRNAs) are key regulators in cancer development. Targeting aberrant miRNA expression offers a promising therapeutic strategy for human cancers.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are small, regulatory non-coding RNAs with critical roles in cellular pathways.
  • Aberrant miRNA expression is a hallmark of human diseases, particularly cancers.
  • miRNAs can function as oncogenes or tumor suppressors, influencing tumorigenesis.

Purpose of the Study:

  • To review the multifaceted roles of miRNAs in cancer pathogenesis.
  • To discuss the diagnostic and therapeutic potential of miRNAs in oncology.
  • To highlight challenges and future perspectives for miRNA-based cancer treatments.

Main Methods:

  • Literature review of miRNA involvement in cancer.
  • Analysis of miRNA dysregulation in various human cancers.
  • Discussion of miRNA-based diagnostic and therapeutic strategies.

Main Results:

  • miRNAs are significantly dysregulated across numerous cancer types.
  • Specific miRNAs can act as oncogenes or tumor suppressors.
  • miRNAs present novel targets for cancer diagnosis and therapy.

Conclusions:

  • Targeting aberrantly expressed miRNAs represents a significant future strategy for cancer diagnosis and treatment.
  • Further research is needed to overcome clinical challenges in miRNA-based therapies.

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...